The Therapeutic Potential of Psychedelic-Assisted Therapy: What the Research Shows
The research on psychedelic-assisted therapy has accelerated significantly over the past two decades. What was largely dormant science — shut down in the early 1970s alongside broader psychedelic prohibition — has re-emerged with rigorous methodology, institutional backing, and results that have surprised even cautious researchers.
This isn't fringe science anymore. Psilocybin and MDMA have both received FDA Breakthrough Therapy designation. Clinical trials are running at Johns Hopkins, NYU, UCSF, Imperial College London, and elsewhere. The data on conditions like treatment-resistant depression, PTSD, and end-of-life anxiety is genuinely compelling.
Understanding what the research actually shows — and what it doesn't — matters for anyone considering this work.
A Brief History
Psychedelic research isn't new. From the 1950s through the early 1970s, researchers including Dr. Humphry Osmond and Dr. Stanislav Grof conducted extensive work with LSD and psilocybin, reporting significant results in the treatment of alcohol use disorder, depression, and anxiety. Over 40,000 patients were treated; more than 1,000 papers were published.
That research came to an abrupt halt when psychedelics were classified as Schedule I controlled substances under the U.S. Controlled Substances Act of 1970. The classification effectively ended clinical trials and made research extremely difficult for the following three decades.
The modern revival began in earnest in the early 2000s, with organizations like MAPS (the Multidisciplinary Association for Psychedelic Studies) and researchers at institutions like Johns Hopkins successfully restarting human trials under rigorous scientific conditions. This new wave of research has been characterized by careful attention to methodology, safety protocols, and a more nuanced understanding of both risks and benefits.
What the Research Shows
Depression
The evidence on psilocybin for depression — including treatment-resistant forms — is among the most robust in the field. A landmark study from Johns Hopkins found that 71% of participants with treatment-resistant depression experienced at least a 50% reduction in depression scores following two psilocybin sessions, with 54% achieving full remission. Effects were still significant at follow-up assessments weeks later.
Imperial College London has conducted important brain imaging research helping to explain the mechanism: psilocybin appears to reduce activity in the default mode network (DMN), the brain region associated with self-referential, ruminative thinking — the kind that characterizes depression. This disruption allows for a kind of psychological flexibility that's difficult to access otherwise.
A large Phase IIb trial published in the New England Journal of Medicine in 2022 found that a 25mg dose of psilocybin produced significant reductions in depression scores compared to placebo, with durability at the three-week follow-up. The field is moving toward Phase III trials.
PTSD
MDMA-assisted therapy for PTSD is arguably the furthest along the regulatory pathway. MAPS Phase 3 trials showed that 88% of participants experienced clinically meaningful improvement, and 67% no longer met criteria for a PTSD diagnosis after three MDMA-assisted therapy sessions. These results substantially exceed outcomes with conventional PTSD treatments.
The proposed mechanism relates to MDMA's ability to reduce fear response while enhancing feelings of safety and social trust. This appears to allow patients to process traumatic memories without being overwhelmed by the autonomic arousal that normally accompanies them — creating a therapeutic window that's difficult to achieve otherwise.
End-of-Life Anxiety
Some of the earliest compelling modern research involved psilocybin and existential distress in patients with terminal illness. Studies at Johns Hopkins and NYU found significant and sustained reductions in depression and anxiety among cancer patients who underwent psilocybin-assisted sessions, with many participants describing the experience as among the most meaningful of their lives. Six months after treatment, improvements were still evident in the majority of participants.
Addiction
Research on psilocybin for tobacco and alcohol use disorders has shown notable results. A Johns Hopkins pilot study on smoking cessation found that 80% of participants had abstained from smoking at six-month follow-up — a success rate considerably higher than conventional cessation programs. Studies on alcohol use disorder have shown similar promise. The mechanism may involve shifts in how people conceptualize their relationship to the addictive substance, combined with increased motivation for change.
How Psychedelic-Assisted Therapy Works
The research consistently shows that the experience alone is not the treatment. Outcomes in clinical trials are strongly associated with the quality of the therapeutic container surrounding the experience — specifically, preparation and integration.
Preparation involves building a therapeutic alliance, establishing clear intentions, reviewing relevant history, and reducing unnecessary anxiety about the experience itself. This phase typically spans multiple sessions before the dosing day.
The experience itself takes place in a carefully designed setting, with trained guides or therapists present throughout. Sessions typically last four to eight hours, depending on the substance and dose.
Integration — the process of making meaning from what emerged and translating it into concrete change — is where the sustained therapeutic work happens. Research suggests that integration support significantly improves the durability of positive outcomes. Without it, insights often fade rather than compound.
This structure reflects a broader finding: psychedelics appear to create windows of increased neuroplasticity — a period where the brain is more capable of forming new connections and revising entrenched patterns. Integration is the work of actually using that window.
Important Caveats
The research is promising but not without complexity.
Not everyone responds well. Some participants have difficult or challenging experiences. The presence of trained support is a meaningful safeguard, not just a formality.
There are genuine contraindications. A personal or family history of psychosis or schizophrenia spectrum conditions warrants serious caution. Certain medications carry risks in combination with psilocybin and MDMA. Proper screening is essential.
The field is still developing. Many trials are relatively small, follow-up periods vary, and the most robust data is concentrated in a few conditions. Enthusiasm should be calibrated — the results are genuinely significant, but they are not a guarantee.
Access remains limited. In Canada, Health Canada's Special Access Program has opened some regulatory pathways, but psychedelic-assisted therapy is not yet widely available within the healthcare system. The landscape is evolving.
The Legal Landscape in British Columbia
In BC, the regulatory environment has been shifting. Exemptions under Section 56 of the Controlled Drugs and Substances Act have been granted for certain practitioners. The Special Access Program has allowed some terminally ill patients to access psilocybin-assisted therapy through approved providers. Research trials are expanding.
The situation is different from recreational decriminalization. Guided therapeutic work with psilocybin in BC exists in a specific regulatory context — one that continues to develop. Anyone working in this space has an obligation to be honest about the current legal framework and how their practice relates to it.
At Woven, we are transparent about the legal context of our work and how it informs what we offer and how we operate.
What This Means for People Considering This Work
The research provides a meaningful foundation. It tells us that these experiences, done carefully and supported well, can produce significant psychological shifts — shifts that are difficult to achieve through conventional approaches and that have demonstrable durability.
It also tells us that the work requires real structure: competent guides, proper screening, genuine preparation, and committed integration. The substance is not the treatment. The container around it is.
If you're exploring this seriously, start with those questions: What does the preparation process look like? What happens after? What's the guide's training and approach? How will my specific situation be assessed?
Those questions will tell you more than any promotional description.
Woven Journeys offers guided psilocybin experiences in the Sea-to-Sky corridor — Vancouver, Squamish, Whistler, and Pemberton, BC.